Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

PURPOSE OF REVIEW: Immune checkpoint inhibitors, such as monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1, have improved the outcome of many malignancies, but serious immune-related cardiovascular adverse events have been observed. Patients’ risk factors for these toxicities are currently bei...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirozzi, Flora, Poto, Remo, Aran, Luisa, Cuomo, Alessandra, Galdiero, Maria Rosaria, Spadaro, Giuseppe, Abete, Pasquale, Bonaduce, Domenico, Marone, Gianni, Tocchetti, Carlo Gabriele, Varricchi, Gilda, Mercurio, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790474/
https://www.ncbi.nlm.nih.gov/pubmed/33415405
http://dx.doi.org/10.1007/s11912-020-01002-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790474/
https://www.ncbi.nlm.nih.gov/pubmed/33415405
http://dx.doi.org/10.1007/s11912-020-01002-w

Ejemplares similares